Valuation: Genpharmasec Limited

Market Cap 432M 4.51M 3.87M 3.62M 3.31M 6.24M 6.31M 42.79M 16.64M 217M 16.94M 16.57M 718M P/E 2024
-545x
P/E 2025 94.5x
Enterprise Value 422M 4.41M 3.78M 3.54M 3.23M 6.1M 6.17M 41.86M 16.28M 212M 16.57M 16.21M 702M EV / Sales 2024
3.47x
EV / Sales 2025 2.96x
Free-Float
56.99%
Yield 2024 *
-
Yield 2025 -
1 day-2.91%
1 week-1.96%
Current month-3.85%
1 month-3.85%
3 months-21.88%
6 months-24.81%
Current year-23.66%
1 week 0.9
Extreme 0.9
1.03
1 month 0.9
Extreme 0.9
1.08
Current year 0.75
Extreme 0.75
1.45
1 year 0.75
Extreme 0.75
2.15
3 years 0.75
Extreme 0.75
8.71
5 years 0.75
Extreme 0.75
11.08
10 years 0.75
Extreme 0.75
18
Manager TitleAgeSince
Director of Finance/CFO 39 01/11/2022
Compliance Officer - 27/03/2024
Director TitleAgeSince
Director/Board Member 57 02/01/2019
Director/Board Member 58 02/01/2019
Director/Board Member - 01/11/2022
Change 5-day change 1-year change 3-year change Capi.($)
-2.91%-1.96%-50.74%-71.35% 5.96M
+0.03%+5.71%-12.01%+12.45% 202B
-0.48%+2.54%+0.20%+14.61% 119B
+1.80%+3.60%+10.65%+81.11% 61.78B
+0.02%-5.31%+29.16%+58.57% 52.35B
-0.66%+4.75%-4.47%-31.14% 51.96B
-1.39%+2.59%+10.70%-9.82% 34.36B
+1.28%-0.52% - - 30.44B
+0.07%+1.94%+42.55%-9.80% 24.87B
+0.44%+1.14%-0.78%+25.42% 24.07B
Average -0.18%+1.71%+2.81%+7.78% 60.06B
Weighted average by Cap. +0.05%+2.83%+1.68%+18.84%

Financials

2024 2025
Net sales 304M 3.18M 2.72M 2.55M 2.33M 4.39M 4.44M 30.13M 11.71M 153M 11.92M 11.66M 505M 337M 3.52M 3.02M 2.82M 2.58M 4.87M 4.92M 33.41M 12.99M 169M 13.22M 12.94M 560M
Net income -1.26M -13.13K -11.25K -10.52K -9.62K -18.16K -18.35K -125K -48.43K -631K -49.29K -48.22K -2.09M 12.31M 129K 110K 103K 94.25K 178K 180K 1.22M 474K 6.18M 483K 472K 20.46M
Net Debt -179M -1.87M -1.6M -1.5M -1.37M -2.58M -2.61M -17.72M -6.89M -89.82M -7.01M -6.86M -297M -9.4M -98.2K -84.16K -78.73K -71.98K -136K -137K -932K -362K -4.72M -369K -361K -15.62M
Logo Genpharmasec Limited
Genpharmasec Limited is an India-based company, which is engaged in the distribution of diagnostic pharma equipment and trading of securities. The Company’s segments include Pharmaceuticals, Trading in Securities, and Laboratory Testing. The Trading in Securities segment invests in the secondary securities market. The Company holds rights to the distribution of equipment, such as i-STAT Analyzers and its Cartridges, manufactured by Abbott Point of Care, USA, all over India. The i-STAT Analyzer is a blood analyzer used in Intensive Care Units (ICUs) of hospitals and provides test results in approximately 10 minutes. The Company’s wholly owned subsidiary includes M/s. Clinigenome India Private Limited.
Employees
10
Date Price Change Volume
25/08/26 INR 1.000 -2.91% 769,590
24/08/26 INR 1.030 +1.98% 452,068
21/08/26 INR 1.010 -0.98% 203,789
20/08/26 INR 1.020 0.00% 103,079
19/08/26 INR 1.020 0.00% 106,426
  1. Stock Market
  2. Stocks
  3. ADIRASA Stock